Metabolic assessment of gliomas using 11C-methionine, [ 18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography

American Journal of Neuroradiology

Volumn 29, Issue 6, 2008, Pages 1176-1182

  Kato, Takayuki ^a,b   Shinoda, J ^a   Nakayama, N ^b   Miwa, K ^a   Okumura, A ^a   Yano, H ^b   Yoshimura, S ^b   Maruyama, T ^c   Muragaki, Y ^c   Iwama, T ^b  

^a Kizawa Memorial Hospital   (Japan)

^b GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE C 11; FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; KI 67 ANTIGEN; METHIONINE C 11; CARBON; CHOLINE; DIAGNOSTIC AGENT; METHIONINE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; ASTROCYTE; ASTROCYTOMA; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; GLIOMA; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; POSITRON EMISSION TOMOGRAPHY; TUMOR CLASSIFICATION; TUMOR DIAGNOSIS; TUMOR LOCALIZATION; BRAIN TUMOR; FEMALE; GENE EXPRESSION PROFILING; MALE; METABOLIC CLEARANCE RATE; METHODOLOGY; MIDDLE AGED; SCINTISCANNING; TISSUE DISTRIBUTION;

ADULT; BRAIN NEOPLASMS; CARBON RADIOISOTOPES; CHOLINE; FEMALE; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION PROFILING; GLIOMA; HUMANS; MALE; METABOLIC CLEARANCE RATE; METHIONINE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 46749098311     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: 10.3174/ajnr.A1008     Document Type: Article

References (34)

1. Delbeke D, Meyerowitz C, Lapidus RL, et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 1995;195:47-52
2. Derlon JM, Bourdet C, Bustany P, et al. [11c]l-Methionine uptake in gliomas. Neurosurgery 1989;25:720-28
3. Herholz K, Holzer T, Bauer B, et al. 11c-Methionine pet for differential diagnosis of low-grade gliomas. Neurology 1998;50:1316-22
4. Kaschten B, Stevenaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998;39:778-85
5. De Witte O, Goldberg I, Wikler D, et al. Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 2001;95:746-50
6. Kim S, Chung JK, Im SH, et al. 11c-Methionine pet as a prognostic marker in patients with glioma: Comparison with 18f-FDG PET. Eur J Nucl Med Mol Imaging 2005;32:52-59
7. Di Chiro G, DeLaPaz RL, Brooks RA, et al. Glucose utilization of cerebral gliomas measured by [18f] fluorodeoxyglucose and positron emission tomography. Neurology 1982;32:1323-29
8. Ogawa T, Inugami A, Hatazawa J, et al. Clinical positron emission tomography for brain tumors: comparison of fludeoxyglucose f 18 and l-methyl-11c-methionine. AJNR Am J Neuroradiol 1996;17:345-53
9. Tateishi U, Yamaguchi U, Seki K, et al. Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [(18)f]fluorodeoxyglucose positron emission tomography. Eur J Nucl Med Mol Imaging 2006;33:683-91
10. Buck A, Schirrmeister H, Kuhn T, et al. FDG uptake in breast cancer: Correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 2002;29:1317-23
11. Avril N, Menzel M, Dose J, et al. Glucose metabolism of breast cancer assessed by 18f-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001;42:9-16
12. Vesselle H, Schmidt RA, Pugsley JM, et al. Lung cancer proliferation correlates with [f-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 2000;6:3837-44
13. Tian M, Zhang H, Oriuchi N, et al. Comparison of 11c-choline PET and FDG PET for the differential diagnosis of malignant tumors. Eur J Nucl Med Mol Imaging 2004;31:1064-72
14. Ohtani T, Kurihara H, Ishiuchi S, et al. Brain tumour imaging with carbon-11 choline: comparison with FDG PET and gadolinium-enhanced MR imaging. Eur J Nucl Med 2001;28:1664-70
15. Hara T, Kosaka N, Shinoura N, et al.PETimaging of brain tumor with [methyl-11c]choline. J Nucl Med 1997;38:842-47
16. Utriainen M, Komu M, Vuorinen V, et al. Evaluation of brain tumor metabolism with [11c]choline PET and 1H-MRS. J Neurooncol 2003;62:329-38
17. Schiffer D, Bosone I, Dutto A, et al. The prognostic role of vessel productive changes and vessel density in oligodendroglioma. J Neurooncol 1999;44:99-107
18. Schiffer D, Dutto A, Cavalla P, et al. Prognostic factors in oligodendroglioma. Can J Neurol Sci 1997;24:313-19
19. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-79
20. Cairncross JG, Macdonald DR, Ramsay DA. Aggressive oligodendroglioma: a chemosensitive tumor. Neurosurgery 1992;31:78-82
21. Kapouleas I, Alavi A, Alves WM, et al. Registration of three-dimensional MR and PET images of the human brain without markers. Radiology 1991;181:731-39
22. Narayanan TK, Said S, Mukherjee J, et al. A comparative study on the uptake and incorporation of radiolabeled methionine, choline and fluorodeoxyglucose in human astrocytoma. Mol Imaging Biol 2002;4:147-56
23. Derlon JM, Petit-Taboue MC, Chapon F, et al. The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study using 18ffluorodeoxyglucose and 11c-l-methylmethionine. Neurosurgery 1997;40:276-87; discussion 287-78
24. Bustany P, Chatel M, Derlon JM, et al. Brain tumor protein synthesis and histological grades: a study by positron emission tomography (PET) with c11-l-methionine. J Neurooncol 1986;3:397-404
25. Plate KH, Breier G, Risau W. Molecular mechanisms of developmental and tumor angiogenesis. Brain Pathol 1994;4:207-18
26. Plate KH, Risau W. Angiogenesis in malignant gliomas. Glia 1995;15:339-47
27. Theurillat JP, Hainfellner J, Maddalena A, et al. Early induction of angiogenetic signals in gliomas of gfap-v-src transgenic mice. Am J Pathol 1999;154:581-90
28. Kracht LW, Friese M, Herholz K, et al. Methyl-[11c]- l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 2003;30:868-73
29. Giammarile F, Cinotti LE, Jouvet A, et al. High and low grade oligodendrogliomas (ODG): correlation of amino-acid and glucose uptakes using PET and histological classifications. J Neurooncol 2004;68:263-74
30. Nariai T, Tanaka Y, Wakimoto H, et al. Usefulness of l-[methyl-11c] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg 2005;103:498-507
31. Hara T, Kondo T, Hara T, et al. Use of 18f-choline and 11c-choline as contrast agents in positron emission tomography imaging-guided stereotactic biopsy sampling of gliomas. J Neurosurg 2003;99:474-79
32. Miwa K, Shinoda J, Yano H, et al. Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: Insight from a PET and MR fusion image study. J Neurol Neurosurg Psychiatry 2004;75:1457-62
33. Levivier M, Massager N, Wikler D, et al. Use of stereotactic PET images in dosimetry planning of radiosurgery for brain tumors: clinical experience and proposed classification. J Nucl Med 2004;45:1146-54
34. Pirotte B, Goldman S, Dewitte O, et al. Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. J Neurosurg 2006;104:238-53